Compare Novavax Inc (NVAX) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Ferrari NV — how do they compare? Novavax Inc trades at $7.89 (market cap $1.31B), while Ferrari NV trades at $406.38 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 54.7× Novavax Inc's market cap, and Ferrari NV pays a 1.04% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | RACE | |
|---|---|---|
Market Cap | $1.31B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $504.09 |
52-Week Low | $6.22 | $314.63 |
Enterprise Value | $889.30M | $73.60B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Ferrari (RACE) trades at $407.76, up 0.24% today, near its pivot point of $407 with bullish technical indicators. The stock shows strong fundamentals with a 22.25% net margin and consistent earnings beats, including Q2 2026 EPS of $2.99 versus $2.83 expected. Revenue growth is steady, reaching $7.15B in 2025, supported by high demand and personalization revenue.
Outlook remains positive with a consensus price target of $462.67, though elevated P/E of 37.93 poses valuation risk. Key opportunities include pricing power and EV expansion, while risks involve economic sensitivity and execution on new models. Analyst sentiment is strongly bullish with 72% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
